Intrathecal administration of autologous mesenchymal stem cells in multiple system atrophy.
Wolfgang SingerAllan B DietzAnita D ZellerTonette L GehrkingJames D SchmelzerAnn M SchmeichelJade A GehrkingMariana D SuarezDavid M SlettenKarla V Minota PachecoElizabeth A CoonPaola SandroniEduardo E BenarrochRobert D FealeyJoseph Y MatsumotoJames H BowerAnhar HassanAndrew McKeonAnthony J WindebankJay N MandrekarPhillip A LowPublished in: Neurology (2019)
This phase I/II study provides Class IV evidence that for patients with early MSA, intrathecal MSC administration is safe, may result in a painful implantation response at high doses, and is associated with dose-dependent efficacy signals.